Amanda K Leonberg-Yoo1, Hocine Tighiouart2, Andrew S Levey1, Gerald J Beck3, Mark J Sarnak4. 1. Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA. 2. Research Design Center/Biostatistics Research Center, Tufts CTSI and Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA. 3. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH. 4. Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA. Electronic address: msarnak@tuftsmedicalcenter.org.
Abstract
BACKGROUND: Low urine potassium excretion, as a surrogate for dietary potassium intake, is associated with higher risk for hypertension and cardiovascular disease in a general population. Few studies have investigated the relationship of urine potassium with clinical outcomes in chronic kidney disease (CKD). STUDY DESIGN: Longitudinal cohort study. SETTING & PARTICIPANTS: The MDRD (Modification of Diet in Renal Disease) Study was a randomized controlled trial (N = 840) conducted in 1989 to 1993 to examine the effects of blood pressure control and dietary protein restriction on kidney disease progression in adults aged 18 to 70 years with CKD stages 2 to 4. This post hoc analysis included 812 participants. PREDICTOR: The primary predictor variable was 24-hour urine potassium excretion, measured at baseline and at multiple time points (presented as time-updated average urine potassium excretion). OUTCOMES: Kidney failure, defined as initiation of dialysis therapy or transplantation, was determined from US Renal Data System data. All-cause mortality was assessed using the National Death Index. RESULTS:Median follow-up for kidney failure was 6.1 (IQR, 3.5-11.7) years, with 9 events/100 patient-years. Median all-cause mortality follow-up was 19.2 (IQR, 10.8-20.6) years, with 3 deaths/100 patient-years. Baseline mean urine potassium excretion was 2.39±0.89 (SD) g/d. Each 1-SD higher baseline urine potassium level was associated with an adjusted HR of 0.95 (95% CI, 0.87-1.04) for kidney failure and 0.83 (95% CI, 0.74-0.94) for all-cause mortality. Results were consistent using time-updated average urine potassium measurements. LIMITATIONS: Analyses were performed using urine potassium excretion as a surrogate for dietary potassium intake. Results are obtained from a primarily young, nondiabetic, and advanced CKD population and may not be generalizable to the general CKD population. CONCLUSIONS:Higher urine potassium excretion was associated with lower risk for all-cause mortality, but not kidney failure.
RCT Entities:
BACKGROUND: Low urine potassium excretion, as a surrogate for dietary potassium intake, is associated with higher risk for hypertension and cardiovascular disease in a general population. Few studies have investigated the relationship of urine potassium with clinical outcomes in chronic kidney disease (CKD). STUDY DESIGN: Longitudinal cohort study. SETTING & PARTICIPANTS: The MDRD (Modification of Diet in Renal Disease) Study was a randomized controlled trial (N = 840) conducted in 1989 to 1993 to examine the effects of blood pressure control and dietary protein restriction on kidney disease progression in adults aged 18 to 70 years with CKD stages 2 to 4. This post hoc analysis included 812 participants. PREDICTOR: The primary predictor variable was 24-hour urine potassium excretion, measured at baseline and at multiple time points (presented as time-updated average urine potassium excretion). OUTCOMES: Kidney failure, defined as initiation of dialysis therapy or transplantation, was determined from US Renal Data System data. All-cause mortality was assessed using the National Death Index. RESULTS: Median follow-up for kidney failure was 6.1 (IQR, 3.5-11.7) years, with 9 events/100 patient-years. Median all-cause mortality follow-up was 19.2 (IQR, 10.8-20.6) years, with 3 deaths/100 patient-years. Baseline mean urine potassium excretion was 2.39±0.89 (SD) g/d. Each 1-SD higher baseline urine potassium level was associated with an adjusted HR of 0.95 (95% CI, 0.87-1.04) for kidney failure and 0.83 (95% CI, 0.74-0.94) for all-cause mortality. Results were consistent using time-updated average urine potassium measurements. LIMITATIONS: Analyses were performed using urine potassium excretion as a surrogate for dietary potassium intake. Results are obtained from a primarily young, nondiabetic, and advanced CKD population and may not be generalizable to the general CKD population. CONCLUSIONS: Higher urine potassium excretion was associated with lower risk for all-cause mortality, but not kidney failure.
Authors: Feng J He; Maciej Marciniak; Christine Carney; Nirmala D Markandu; Vidya Anand; William D Fraser; R Neil Dalton; Juan C Kaski; Graham A MacGregor Journal: Hypertension Date: 2010-01-18 Impact factor: 10.190
Authors: Jiang He; Katherine T Mills; Lawrence J Appel; Wei Yang; Jing Chen; Belinda T Lee; Sylvia E Rosas; Anna Porter; Gail Makos; Matthew R Weir; L Lee Hamm; John W Kusek Journal: J Am Soc Nephrol Date: 2015-09-17 Impact factor: 10.121
Authors: J T Holbrook; K Y Patterson; J E Bodner; L W Douglas; C Veillon; J L Kelsay; W Mertz; J C Smith Journal: Am J Clin Nutr Date: 1984-10 Impact factor: 7.045
Authors: Nancy R Cook; Eva Obarzanek; Jeffrey A Cutler; Julie E Buring; Kathryn M Rexrode; Shiriki K Kumanyika; Lawrence J Appel; Paul K Whelton Journal: Arch Intern Med Date: 2009-01-12
Authors: Andrew Smyth; Daniela Dunkler; Peggy Gao; Koon K Teo; Salim Yusuf; Martin J O'Donnell; Johannes F E Mann; Catherine M Clase Journal: Kidney Int Date: 2014-06-11 Impact factor: 10.612
Authors: Casey M Rebholz; Lesley A Inker; Yuan Chen; Menglu Liang; Meredith C Foster; John H Eckfeldt; Paul L Kimmel; Ramachandran S Vasan; Harold I Feldman; Mark J Sarnak; Chi-Yuan Hsu; Andrew S Levey; Josef Coresh Journal: Am J Kidney Dis Date: 2017-06-23 Impact factor: 8.860
Authors: Yoko Narasaki; Amy S You; Shaista Malik; Linda W Moore; Rachelle Bross; Mackenzie K Cervantes; Andrea Daza; Csaba P Kovesdy; Danh V Nguyen; Kamyar Kalantar-Zadeh; Connie M Rhee Journal: Am J Clin Nutr Date: 2022-10-06 Impact factor: 8.472
Authors: Martin Gritter; Rosa D Wouda; Stanley M H Yeung; Michiel L A Wieërs; Frank Geurts; Maria A J de Ridder; Christian R B Ramakers; Liffert Vogt; Martin H de Borst; Joris I Rotmans; Ewout J Hoorn Journal: J Am Soc Nephrol Date: 2022-05-24 Impact factor: 14.978
Authors: Martin Gritter; Liffert Vogt; Stanley M H Yeung; Rosa D Wouda; Christian R B Ramakers; Martin H de Borst; Joris I Rotmans; Ewout J Hoorn Journal: Nephron Date: 2018-06-29 Impact factor: 2.847